Clinical Trials in Fujian, China
3 recruiting
Showing 1–10 of 10 trials
Recruiting
Phase 3
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Breast Neoplasms
Merck Sharp & Dohme LLC1,000 enrolled149 locationsNCT07060807
Recruiting
Phase 1Phase 2
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Triple-Negative Breast CancerEndometrial CancerPrimary Peritoneal Carcinoma+12 more
Genmab764 enrolled67 locationsNCT05579366
Recruiting
Phase 2
SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC
Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)
Fudan University66 enrolled3 locationsNCT07451795
Recruiting
Phase 3
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Breast Cancer
Daiichi Sankyo250 enrolled86 locationsNCT05950945
Recruiting
Phase 3
QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
Nasopharyngeal CancerNasopharyngeal Cancinoma (NPC)
Sun Yat-Sen University Cancer Center580 enrolled19 locationsNCT06749899
Recruiting
Phase 2
HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors
Advanced Solid Tumor
Hansoh BioMedical R&D Company220 enrolled21 locationsNCT06112704
Recruiting
The Chinese Familial Alzheimer's Network
Alzheimer DiseaseFamilial Alzheimer Disease (FAD)
Capital Medical University40,000 enrolled65 locationsNCT03657732
Recruiting
China Cognition and Aging Study
Mild Cognitive Impairment (MCI)Alzheimer Disease, Late OnsetFamilial Alzheimer Disease (FAD)+3 more
Capital Medical University100,000 enrolled65 locationsNCT03653156
Recruiting
Phase 2
A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma (Icc)
Beijing InnoCare Pharma Tech Co., Ltd.70 enrolled44 locationsNCT05678270
Recruiting
Phase 2
Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.
Ovarian NeoplasmsOvarian Diseases
Fujian Cancer Hospital37 enrolled1 locationNCT05753826